PMID- 37595372
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231011
IS  - 1873-5835 (Electronic)
IS  - 0145-2126 (Linking)
VI  - 133
DP  - 2023 Oct
TI  - Treatment strategy at the decision for allogeneic transplantation in patients 
      with myelodysplastic syndrome in the era of azacitidine: A KSGCT prospective 
      study.
PG  - 107371
LID - S0145-2126(23)00636-7 [pii]
LID - 10.1016/j.leukres.2023.107371 [doi]
AB  - The optimal bridge strategy at the decision for allogeneic hematopoietic stem 
      cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is 
      unclear. We performed a prospective observational study in which 110 patients 
      with MDS who were decided to undergo HSCT were enrolled. Among these 110 
      patients, 77 patients were enrolled in this study within 1 month from the 
      decision for HSCT. Among these 77 patients, 13 patients had a human leukocyte 
      antigen (HLA)-matched sibling, 54 patients started an unrelated donor search, and 
      the other 10 patients directly selected cord blood (CB) at the decision for HSCT, 
      and 13 (100%), 38 (70.4%), and 9 (90%) patients actually underwent HSCT within 1 
      year, respectively. The overall survival (OS) at 1 year from their enrollment was 
      70.9%, and the selection of azacitidine use at the decision for HSCT was not 
      associated with OS. Among 60 of the 77 patients who actually underwent HSCT 
      within a year from their enrollment, a lower relapse rate after HSCT was observed 
      in those who selected CB at the decision to undergo HSCT. However, this 
      preferable effect of CB selection disappeared when patients who were enrolled in 
      this study in > 1 month from the decision for HSCT were additionally included in 
      the analyses. In conclusion, the selection of bridge strategy at the decision for 
      HSCT did not affect outcomes in patients with MDS. The immediate performance of 
      HSCT may be associated with better outcomes.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Kako, Shinichi
AU  - Kako S
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan. Electronic address: shinichikako@asahi-net.email.ne.jp.
FAU - Kimura, Shun-Ichi
AU  - Kimura SI
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan.
FAU - Wada, Hidenori
AU  - Wada H
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan.
FAU - Komiya, Yusuke
AU  - Komiya Y
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan.
FAU - Nakasone, Hideki
AU  - Nakasone H
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan.
FAU - Sakurai, Masatoshi
AU  - Sakurai M
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Kato, Jun
AU  - Kato J
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Tanaka, Masatsugu
AU  - Tanaka M
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Fujii, Eriko
AU  - Fujii E
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Tachibana, Takayoshi
AU  - Tachibana T
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Yamamoto, Wataru
AU  - Yamamoto W
AD  - Department of Hematology, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Hagihara, Maki
AU  - Hagihara M
AD  - Department of Hematology and Clinical Immunology, Yokohama City University School 
      of Medicine, Yokohama, Japan.
FAU - Watanabe, Reiko
AU  - Watanabe R
AD  - Department of Hematology, Saitama Medical Center, Saitama Medical University, 
      Saitama, Japan.
FAU - Yokota, Akira
AU  - Yokota A
AD  - Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
FAU - Nakano, Hirofumi
AU  - Nakano H
AD  - Division of Hematology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
FAU - Mori, Takehiko
AU  - Mori T
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan; Department of Hematology, Tokyo Medical and Dental 
      University, Tokyo, Japan.
FAU - Nakaseko, Chiaki
AU  - Nakaseko C
AD  - Department of Hematology, Chiba University Hospital, Chiba, Japan; Department of 
      Hematology, International University of Health and Welfare, Narita, Japan.
FAU - Kanamori, Heiwa
AU  - Kanamori H
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Okamoto, Shinichiro
AU  - Okamoto S
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan.
FAU - Kanda, Yoshinobu
AU  - Kanda Y
AD  - Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, 
      Japan; Division of Hematology, Department of Medicine, Jichi Medical University, 
      Shimotsuke, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230807
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - M801H13NRU (Azacitidine)
SB  - IM
MH  - Humans
MH  - Azacitidine/therapeutic use
MH  - Prospective Studies
MH  - *Myelodysplastic Syndromes
MH  - Transplantation, Homologous
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Allogeneic transplantation
OT  - Azacitidine
OT  - Myelodysplastic syndrome
OT  - Transplantation decision
COIS- Declaration of Competing Interest S.K. has received honoraria from Nippon 
      Shinyaku. S.K. has received honoraria from Nippon Shinyaku. H.N. has received 
      honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Bristol-Myers 
      Squibb, Celgene, Pfizer, Novartis, Janssen Pharmaceutical, Eisai, Chugai 
      Pharmaceutical, and Nippon Shinyaku., and a subsidy from MSD. M.S. has received 
      research funding from Nippon Shinyaku. T.T. has received honoraria from Otsuka, 
      Novartis, Pfizer, Daiichi Sankyo, Astellas, MSD, and Chugai.
EDAT- 2023/08/19 11:42
MHDA- 2023/10/02 06:42
CRDT- 2023/08/18 18:03
PHST- 2023/02/20 00:00 [received]
PHST- 2023/06/25 00:00 [revised]
PHST- 2023/08/05 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/08/19 11:42 [pubmed]
PHST- 2023/08/18 18:03 [entrez]
AID - S0145-2126(23)00636-7 [pii]
AID - 10.1016/j.leukres.2023.107371 [doi]
PST - ppublish
SO  - Leuk Res. 2023 Oct;133:107371. doi: 10.1016/j.leukres.2023.107371. Epub 2023 Aug 
      7.